Maximum Dose of Mounjaro for Type 2 Diabetes
The maximum prescribed dose of Mounjaro (tirzepatide) for type 2 diabetes management is 15 mg injected subcutaneously once weekly in adults. 1
Dosing Algorithm
According to the FDA-approved prescribing information, follow this specific titration schedule 1:
Starting dose:
- Begin with 2.5 mg subcutaneously once weekly
- This dose is for treatment initiation only and is NOT intended for glycemic control
Dose escalation:
- After 4 weeks, increase to 5 mg once weekly
- If additional glycemic control is needed, increase in 2.5 mg increments
- Wait at least 4 weeks on each dose before escalating
- Continue escalating: 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (maximum)
The approved maintenance doses are 5 mg, 10 mg, and 15 mg per week 2, with 15 mg representing the ceiling dose for adults with type 2 diabetes.
Clinical Context
The 15 mg maximum dose has demonstrated robust efficacy in clinical trials. In the SURMOUNT-2 trial specifically evaluating patients with type 2 diabetes and obesity, the 15 mg dose achieved an average weight reduction of 14.7% and HbA1c reduction of 2.2%, with over 87% of patients reaching HbA1c targets below 7% 2. The SURPASS trials confirmed HbA1c reductions of 1.9% to 2% across the dose range 2.
Important Prescribing Caveats
Slow titration is essential to minimize gastrointestinal adverse events (nausea, vomiting, diarrhea), which are the most common side effects and occur primarily during dose escalation 2, 1. The monthly escalation schedule built into the FDA labeling specifically addresses this tolerability concern.
Do not exceed 15 mg weekly - this is both the maximum approved dose and the highest dose studied in the pivotal trials. There is no evidence supporting higher doses, and doing so would be off-label without safety or efficacy data.
Pediatric exception: For pediatric patients aged 10 years and older with type 2 diabetes, the maximum dose is lower at 10 mg once weekly 1.